Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the expected roles and responsibilities of management) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA ... transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection against ... operator control device that will increase healthcare worker safety and reduce financial costs. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from ... first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members ... course combines students from both universities and is taught on both continents. , ...
(Date:6/30/2015)... -- NASA astronaut Kjell Lindgren , who is making final ... to the International Space Station , will be available ... Tuesday, July 7. Lindgren will participate from the ... . The interviews will be preceded at 7:30 a.m. ... To schedule an interview, media must contact ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
Breaking Biology Technology:Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... WOBURN, Mass., Nov. 26 Covaris Incorporated today,announced that ... shipment,of its 500th instrument unit and continued another successful ... Covaris is both,strengthening its sales and marketing organization as ... , The Covaris ...
... TOKYO and CAMBRIDGE, England, November 26 Sosei,Group Corporation ... that it has out-licensed its IP and Know How,relating ... ("Treague"), a,Cambridge, UK based pharma company, for the treatment ... Mefloquine is a highly efficacious anti-malarial drug that ...
... ANDS ) announced today that it will present at ... 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the ... Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will ... ANA598 and ANA773 in hepatitis C and ANA773 in cancer. , ...
Cached Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria 2Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ... Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten ... Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die forensische ... Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
(Date:6/15/2015)... Conn. , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces that ... be showcased to media at Digital Experience! @ NYC June ... summer showcase of the latest innovation in technology to over ... will be held at the Metropolitan Pavilion in ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... of a mathematical model, suggest that international cooperation to ... deal with an emerging pandemic. , 'Bird flu'(avian H5N1 ... because it rarely passes between people. If it does ... develop a vaccine effective against the new virus. Public ...
... normally suppress tumor growth. Now, for the first time, MIT ... mice can cause tumors to shrink or disappear. , ... is a promising target for human cancer drugs. , ... human tumors in which this pathway is blocked, they may ...
... researchers have identified a cellular protein that interferes with ... help scientists develop new drugs to fight the virus. ... “p21-activated kinase 1?(PAK1), was discovered by scientists at the ... describe their findings in an article in the current ...
Cached Biology News:Reactivated gene shrinks tumors 2Reactivated gene shrinks tumors 3Protein found that slows hepatitis C growth in liver cells 2